

## PUBLIC ANNOUNCEMENT



(Please scan the QR Code to view the DRHP)



# NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Our Company was originally incorporated as 'Max Bupa Health Insurance Limited' at New Delhi, Delhi as a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 5, 2008, issued by the Assistant Registrar of Companies, National Capital Territory of Delhi and Haryana and was granted its certificate for commencement of business on December 23, 2008 by the Deputy Registrar of Companies, National Capital Territory of Delhi and Haryana. Thereafter, the name of our Company was changed to 'Max Bupa Health Insurance Company Limited' pursuant to a fresh certificate of incorporation dated July 30, 2009 issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana at New Delhi (now known as Registrar of Companies, Delhi and Haryana (the "RoC")). The name of our Company was further changed to 'Niva Bupa Health Insurance Company Limited' pursuant to a fresh certificate of incorporation dated July 5, 2021 issued by the RoC. For further details in relation to the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 229 of the draft red herring prospectus June 29, 2024 (the "DRHP" or the "Draft Red Herring Prospectus").

**Registered Office:** C-98, 1st Floor Lajpat Nagar, Part 1, South Delhi, New Delhi – 110 024, Delhi, India; **Corporate Office:** 14th Floor, Capital Cyberscape, Sector-59, Gurugram – 122 102, Haryana, India  
**Telephone:** +91 124 635 4900; **Contact Person:** Rajat Sharma, Company Secretary and Compliance Officer; **E-mail:** Investor@nivabupa.com; **Website:** www.nivabupa.com; **Corporate Identity Number:** U66000DL2008PLC182918; **IRDAI Registration Number:** 145

## THE PROMOTERS OF OUR COMPANY ARE: BUPA SINGAPORE HOLDINGS PTE. LTD. AND BUPA INVESTMENTS OVERSEAS LIMITED ("BIOL")

## CORRIGENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED JUNE 29, 2024 : NOTICE TO INVESTORS (THE "CORRIGENDUM")

This is with reference to the DRHP filed by our Company with the SEBI and the Stock Exchanges.

Potential Bidders may note the following: In addition to the Promoter Group members disclosed on pages 255-257 of the DRHP in "Our Promoters and Promoter Group" section, the following entities also formed part of the Promoter Group as on the date of the DRHP in accordance with Regulation 2(1)(pp) of the SEBI ICDR Regulations:

- Advanced Skincare S.L.;
- Clinica Dermatologica Centrodem 2001;
- Centrum Medyczne Omega H Skowerska Sp. z.o.o.;
- Ortopedicum Sp. z.o.o.;
- Smart Smile Sp. z.o.o.; and
- Centrum Edukacyjne Medycyny Sportowej Sp. z.o.o.

("Additional Promoter Group Entities")

Accordingly, all references to the term 'Promoter Group' in the DRHP will include the Additional Promoter Group Entities. As on date of the DRHP, the Additional Promoter Group Entities were in compliance with Regulation 5 of the SEBI ICDR Regulations, as applicable.

Please note that subsequent to the date of filing of the DRHP, BIOL's indirect shareholding in Centrum Edukacyjne Medycyny Sportowej Sp. Z.o.o. (one of the Additional Promoter Group Entities) has been completely divested. Accordingly, as on the date of this Corrigendum, Centrum Edukacyjne Medycyny Sportowej Sp. Z.o.o. is not a part of the Promoter Group in terms of the SEBI ICDR Regulations.

The information in this Corrigendum supplements the information in the DRHP and the above changes are to be read in conjunction with the DRHP and accordingly, relevant references in the DRHP stand updated pursuant to the disclosures in this Corrigendum. This Corrigendum does not reflect all the changes that have occurred between the date of filing of the DRHP with the SEBI and the Stock Exchanges and the date hereof, and accordingly, does not include all the changes and/or updates that will be included in the Red Herring Prospectus and the Prospectus. The DRHP will be suitably updated, pursuant to the aforementioned changes, in the Red Herring Prospectus and the Prospectus, as and when filed with the RoC, the SEBI and the Stock Exchanges.

All capitalized terms used in this Corrigendum shall, unless the context otherwise requires, have the meaning ascribed to them in the DRHP.

This Corrigendum shall be made available to the public for comments, if any, for a period of 7 days, from the date of this Corrigendum. Our Company hereby invites the public to give their comments on the Corrigendum dated September 3, 2024 with respect to disclosures made in it. The members of public are requested to send a copy of their comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein below. All comments must be received by SEBI and/or our Company and/or the BRLMs and/or the Company Secretary and Compliance Officer of our Company at their respective addresses mentioned herein below in relation to the Offer on or before 5:00 p.m. on September 10, 2024, i.e. the 7<sup>th</sup> day from the aforesaid date of the Corrigendum.

### BOOK RUNNING LEAD MANAGERS

<p><b>ICICI Securities Limited</b>                      ICICI Venture House                      Appasaheb Marathe Marg                      Prabhadevi, Mumbai – 400 025                      Maharashtra, India  <b>Tel:</b> +91 22 6807 7100  <b>E-mail:</b> nivabupa ipo@icicisecurities.com  <b>Website:</b> www.icicisecurities.com  <b>Investor Grievance ID:</b> customercare@icicisecurities.com  <b>Contact Person:</b> Harsh Thakkar/                      Abhijit Diwan  <b>SEBI Registration No:</b> INM000011179</p>	<p><b>Morgan Stanley India Company Private Limited</b>                      18th Floor, Tower 2, One World Center                      Plot 841, Jupiter Textile Mill Compound                      Senapati Bapat Marg, Lower Parel                      Mumbai – 400 013 Maharashtra, India  <b>Tel:</b> +91 22 6118 1000  <b>E-mail:</b> nivabupaipo@morganstanley.com  <b>Website:</b> www.morganstanley.com/india  <b>Investor Grievance ID:</b> investors_india@morganstanley.com  <b>Contact Person:</b> Shantanu Tilak  <b>SEBI Registration No:</b> INM000011203</p>	<p><b>Kotak Mahindra Capital Company Limited</b>                      1st Floor, 27 BKC, Plot No. C – 27                      'G' Block, Bandra Kurla Complex                      Bandra (East), Mumbai – 400 051                      Maharashtra, India  <b>Tel:</b> +91 22 4336 0000  <b>E-mail:</b> nivabupa ipo@kotak.com  <b>Website:</b> https://investmentbank.kotak.com  <b>Investor Grievance ID:</b> kmccredressal@kotak.com  <b>Contact person:</b> Ganesh Rane  <b>SEBI Registration No:</b> INM000008704</p>	<p><b>Axis Capital Limited</b>                      1st Floor, Axis House                      P.B. Marg,                      Worli                      Mumbai – 400 025                      Maharashtra, India  <b>Tel:</b> +91 22 4325 2183  <b>E-mail:</b> nivabupa ipo@axiscap.in  <b>Website:</b> www.axiscapital.co.in  <b>Investor Grievance ID:</b> complaints@axiscap.in  <b>Contact Person:</b> Jigar Jain  <b>SEBI Registration No:</b> INM000012029</p>	<p><b>HDFC Bank Limited</b>                      Investment Banking Group, Unit No. 701,                      702 and 702-A, 7th Floor, Tower 2 and 3,                      One International Centre, Senapati Bapat                      Marg, Prabhadevi, Mumbai – 400 013                      Maharashtra, India.  <b>Tel:</b> +91 22 3395 8233  <b>E-mail:</b> nivabupa ipo@hdfcbank.com  <b>Website:</b> www.hdfcbank.com  <b>Investor Grievance ID:</b> investor.redressal@hdfcbank.com  <b>Contact Person:</b> Sanjay Chudasama  <b>SEBI Registration No.:</b> INM000011252</p>	<p><b>Motilal Oswal Investment Advisors Limited</b>                      10th Floor, Motilal Oswal Tower                      Rahimtullah Sayani Road                      Opposite Parel ST Depot, Prabhadevi                      Mumbai – 400 025 Maharashtra, India  <b>Tel:</b> +91 22 7193 4380  <b>E-mail:</b> nivabupa ipo@motilaloswal.com  <b>Website:</b> www.motilaloswalgroup.com  <b>Investor Grievance ID:</b> moiaplredressal@motilaloswal.com  <b>Contact Person:</b> Kunal Thakkar/                      Sankita Ajinkya  <b>SEBI Registration No:</b> INM000011005</p>

### REGISTRAR TO THE OFFER



#### KFin Technologies Limited

Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareedi 500 032 Telangana, India.

**Tel:** +91 40 6716 2222; **E-mail:** nivabupa ipo@kfintech.com; **Website:** www.kfintech.com; **Investor Grievance ID:** einward.ris@kfintech.com; **Contact Person:** M Murali Krishna; **SEBI Registration Number:** INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

On behalf of the Board of Directors

Sd/-

Rajat Sharma

Company Secretary and Compliance Officer

Place : New Delhi

Date : September 3, 2024

NIVA BUPA HEALTH INSURANCE COMPANY LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the DRHP dated June 29, 2024 with SEBI and thereafter with the Stock Exchanges. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges i.e., BSE at www.bseindia.com, NSE at www.nseindia.com, the websites of the BRLMs, i.e. ICICI Securities Limited at www.icicisecurities.com, Morgan Stanley India Company Private Limited at www.morganstanley.com/india, Kotak Mahindra Capital Company Limited at https://investmentbank.kotak.com, Axis Capital Limited at www.axiscapital.co.in, HDFC Bank Limited at www.hdfcbank.com and Motilal Oswal Investment Advisors Limited at www.motilaloswalgroup.com and the website of our Company at www.nivabupa.com. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "Risk Factors" on page 25 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) under Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions" as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.